Last reviewed · How we verify
Osteomalacia
Approved treatments
- Infuvite Adult · Novartis
- Hornel · Taisho Pharmaceutical
- Vitamin D3
- Drisdol · Esjay Pharma
- Crysvita · Ultragenyx Pharm Inc
Burosumab-twza binds to and inhibits FGF23, restoring renal phosphate reabsorption and increasing 1,25 dihydroxy vitamin D levels. - Calciferol · Department of Medical Services Ministry of Public Health of Thailand
- CRYSVITA · KYOWA KIRIN
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Osteomalacia patent landscape — cliff calendar, originator estates, attackable patents
- Osteomalacia treatment landscape brief
- Osteomalacia treatment updates RSS
Frequently asked questions about Osteomalacia
What drugs treat Osteomalacia?
Tracked treatments include Infuvite Adult, Hornel, Vitamin D3, Drisdol, Crysvita, Calciferol, CRYSVITA.
What is the treatment for Osteomalacia?
Standard treatment for Osteomalacia includes Infuvite Adult, Hornel, Vitamin D3, Drisdol, Crysvita. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Osteomalacia patent cliff · Osteomalacia CI report
- Treatment: Infuvite Adult · Novartis
- Treatment: Hornel · Taisho Pharmaceutical
- Treatment: Vitamin D3
- Treatment: Drisdol · Esjay Pharma
- Treatment: Crysvita · Ultragenyx Pharm Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing